Dengue vaccines: Are they safe for travelers?

Halstead, Scott B.; Aguiar, Maíra

doi:10.1016/j.tmaid.2016.06.005

Cited by 17 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is probable that the higher efficacy of Dengvaxia in individuals older than 9 years is more dependent on the occurrence of previous infections than on the increasing age per se ( [25,26,28,52]). This would mean that the vaccine efficacy is poor and a little better only in the case of previous Dengue infection.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine

Maier

Huang

Massad

et al. 2017

Mathematical Biosciences

View full text Add to dashboard Cite

Highlights• Mathematical model to analyse the optimal vaccination age against Dengue in Brazil.• Use epidemiological data from Brazil.• Consider both hospitalisation and lethality risks.• Model possible Dengue Antibody Enhancement.• Calculations repeated with third and fourth infections asymptomatic. AbstractIn this paper we study a mathematical model to analyse the optimal vaccination age against Dengue in Brazil. Data from Brazil are used to estimate the basic reproduction numbers for each of the four Dengue serotypes and then the optimal vaccination age is calculated using a method due to Hethcote [1]. The vaccine has different efficacies against each serotype. Vaccination that is too early is ineffective as individuals are protected by maternal antibodies but leaving vaccination until later may allow the disease to spread.First of all the optimal vaccination ages are calculated where there is just one serotype in circulation and then when there are multiple serotypes. The calculations are done using data both assuming constant vaccine efficacy and agedependent vaccine efficacy against a given serotype. The multiple serotype calculations are repeated assuming that the first infection is a risky infection and that it is not (to model Dengue Antibody Enhancement). The calculations are then repeated when any third or fourth Dengue infections are asymptomatic, so that two Dengue infections with different serotypes provide effective permanent immunity. The calculations are also repeated when the age-dependent risk function (fitted to Brazilian data) is hospitalisation from Dengue and when it is mortality due to Dengue. We find a wide variety of optimal vaccination ages depending on both the serotypes in circulation and the assumptions of the model.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine

Maier

Huang

Massad

et al. 2017

Mathematical Biosciences

View full text Add to dashboard Cite

show abstract

“…26 As regards preventive measures, a tetravalent vaccine is commercially available. 27 However, the drawback of this vaccine is its limited efficacy and potentially severe side-effects 28 and thus has limited use in clinical practice. 29 In our study, there was no statistical evidence that the number of platelet infusions was reduced in association with adjuvant homeopathy.…”

Section: Discussionmentioning

confidence: 99%

Effect of Adjuvant Homeopathy with Usual Care in Management of Thrombocytopenia Due to Dengue: A Comparative Cohort Study

Nayak

Chadha²,

Jain

et al. 2019

Homeopathy

View full text Add to dashboard Cite

Background Dengue is an emerging threat to public health. At present, no clear modalities are available for the prevention and management of thrombocytopenia due to dengue. This article reports the clinical outcomes of integrative homeopathic care in a hospital setting during a severe outbreak of dengue in New Delhi, India, during the period September to December 2015. Methods Based on preference, 138 patients received a homeopathic medicine along with usual care (H+UC), and 145 patients received usual care (UC) alone. Assessment of thrombocytopenia (platelet count < 100,000/mm3) was the main outcome measure. Kaplan–Meier analysis enabled comparison of the time taken to reach a platelet count of 100,000/mm3. Results There was a statistically significantly greater rise in platelet count on day 1 of follow-up in the H+UC group compared with UC alone (mean difference = 12,337; 95% confidence interval [CI], 5,421 to 19,252; p = 0.001). This trend persisted until day 5 (mean difference = 14,809; 95% CI, 1,615 to 28,004; p = 0.02). The time taken to reach a platelet count of 100,000/mm3 was nearly 2 days earlier in the H+UC group compared with UC alone (H+UC: 3.44 days ± standard error of the mean [SEM] 0.18; 95% CI, 3.08 to 3.80; UC: 5.28 days ± SEM 0.29; 95% CI, 4.71 to 5.86; p < 0.001). Conclusion These results suggest a positive role of adjuvant homeopathy in thrombocytopenia due to dengue. Randomized controlled trials may be conducted to obtain more insight into the comparative effectiveness of this integrative approach.

show abstract

“…It is important to note that a safe, effective and affordable dengue vaccine against the four strains offers an important tool to reach the WHO goal of reducing dengue morbidity by at least 25% and mortality by at least 50% by 2020 68 . The first dengue vaccine, Dengvaxiar(CYD-TDV) (developed by Sanofi Pasteur ), was licensed in Mexico in 2015 69 ; and two dengue vaccine candidates (developed by Butantan and Takeda) entered the Phase III trails in early 2016 70 71 72 . Our study should not serve as a discouragement to the development of these dengue vaccine products, but rather we determine conditions under which dengue vaccination can contribute to the prevention and control of dengue without inducing significant increase in Zika infection.…”

Section: Conclusion and Discussionmentioning

confidence: 99%

Implication of vaccination against dengue for Zika outbreak

Tang

Xiao

2016

Sci Rep

View full text Add to dashboard Cite

Zika virus co-circulates with dengue in tropical and sub-tropical regions. Cases of co-infection by dengue and Zika have been reported, the implication of this co-infection for an integrated intervention program for controlling both dengue and Zika must be addressed urgently. Here, we formulate a mathematical model to describe the transmission dynamics of co-infection of dengue and Zika with particular focus on the effects of Zika outbreak by vaccination against dengue among human hosts. Our analysis determines specific conditions under which vaccination against dengue can significantly increase the Zika outbreak peak, and speed up the Zika outbreak peak timing. Our results call for further study about the co-infection to direct an integrated control to balance the benefits for dengue control and the damages of Zika outbreak.

show abstract

Dengue vaccines: Are they safe for travelers?

Cited by 17 publications

References 48 publications

Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine

Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine

Effect of Adjuvant Homeopathy with Usual Care in Management of Thrombocytopenia Due to Dengue: A Comparative Cohort Study

Implication of vaccination against dengue for Zika outbreak

Contact Info

Product

Resources

About